Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Relugolix (Myovant Sciences/Takeda) Drug Analysis 2017-2026 -

Research and Markets
Posted on: 15 Feb 18

The "Drug Analysis: Relugolix" drug pipelines has been added to's offering.

Relugolix (Myovant Sciences/Takeda) is a gonadotropin-releasing hormone (GnRH) receptor antagonist that directly inhibits GnRH receptors, rapidly reducing the circulating gonadotropin's luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and leading to the suppression of testosterone in men.

This mechanism of action stands in contrast to GnRH agonists that, over time, down-regulate and desensitize GnRH receptors in the pituitary, leading to reduced secretion of LH and downstream testosterone. GnRH agonists are also accompanied by an initial surge in testosterone known as a flare that typically requires co-administration of antiandrogens to help prevent flare side effects such as skeletal pain, spinal cord compression, and, very rarely, death.

Relugolix is a GnRH receptor antagonist being trialed in androgen-sensitive advanced prostate cancer patients in the Phase III HERO trial. Relugolix is similar to the approved GnRH antagonist Firmagon (degarelix; Ferring/Astellas), as both drugs deplete androgen levels without an accompanying flare of testosterone that occurs with GnRH agonist treatment.

Despite this advantage, GnRH agonists like leuprolide continue to dominate treatment of hormone-sensitive prostate cancer due to their established efficacy, physician familiarity, and convenient dosing schedules. Thus, relugolix faces competition not only from Firmagon, but from several GnRH agonists as well, which will significantly limit the drug's commercial potential.

Key Topics Covered:

List of Figures

Figure 1: Relugolix for prostate cancer - SWOT analysis

Figure 2: Drug assessment summary of relugolix for prostate cancer

Figure 3: Drug assessment summary of relugolix for prostate cancer

Figure 4: Relugolix sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Relugolix drug profile

Table 2: Relugolix Phase III trials in prostate cancer

Table 3: Relugolix Phase II data in prostate cancer

Table 4: Relugolix sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this drug pipelines report visit

View source version on

Business Wire

Last updated on: 15/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.